Navidea Biopharmaceuticals Stock Forecast, Price & News

-0.01 (-0.58 %)
(As of 07/28/2021 03:17 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume334 shs
Average Volume252,817 shs
Market Capitalization$49.63 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive NAVB News and Ratings via Email

Sign-up to receive the latest news and ratings for Navidea Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Navidea Biopharmaceuticals logo

About Navidea Biopharmaceuticals

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages. Its CD206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. Further, the company offers NAV4694 and NAV5001, a neuro-tracer product candidates. In addition, it is developing diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform; and various therapeutic development programs. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.84 out of 5 stars

Medical Sector

485th out of 2,210 stocks

Diagnostic Substances Industry

7th out of 38 stocks

Analyst Opinion: 3.5Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Frequently Asked Questions

Is Navidea Biopharmaceuticals a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Navidea Biopharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Navidea Biopharmaceuticals stock.
View analyst ratings for Navidea Biopharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Navidea Biopharmaceuticals?

Wall Street analysts have given Navidea Biopharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Navidea Biopharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals saw a increase in short interest in June. As of June 15th, there was short interest totaling 181,000 shares, an increase of 30.2% from the May 31st total of 139,000 shares. Based on an average daily volume of 193,700 shares, the days-to-cover ratio is presently 0.9 days. Currently, 0.9% of the company's stock are short sold.
View Navidea Biopharmaceuticals' Short Interest

When is Navidea Biopharmaceuticals' next earnings date?

Navidea Biopharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for Navidea Biopharmaceuticals

How were Navidea Biopharmaceuticals' earnings last quarter?

Navidea Biopharmaceuticals, Inc. (NYSEAMERICAN:NAVB) released its quarterly earnings results on Monday, May, 10th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.08) by $0.03. The biopharmaceutical company had revenue of $0.12 million for the quarter, compared to the consensus estimate of $0.60 million. Navidea Biopharmaceuticals had a negative trailing twelve-month return on equity of 109.24% and a negative net margin of 1,248.87%.
View Navidea Biopharmaceuticals' earnings history

How has Navidea Biopharmaceuticals' stock been impacted by COVID-19?

Navidea Biopharmaceuticals' stock was trading at $0.96 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NAVB stock has increased by 78.1% and is now trading at $1.71.
View which stocks have been most impacted by COVID-19

What price target have analysts set for NAVB?

2 brokers have issued 12 month price targets for Navidea Biopharmaceuticals' shares. Their forecasts range from $7.00 to $8.00. On average, they anticipate Navidea Biopharmaceuticals' stock price to reach $7.50 in the next year. This suggests a possible upside of 338.6% from the stock's current price.
View analysts' price targets for Navidea Biopharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Navidea Biopharmaceuticals' key executives?

Navidea Biopharmaceuticals' management team includes the following people:
  • Mr. Jed A. Latkin, CEO, COO, CFO & Director (Age 47, Pay $739.99k)
  • Dr. Michael Stanley Rosol Ph.D., Chief Medical Officer (Age 52, Pay $282.45k)
  • Erika Gibson, Director of Fin. & Admin.
  • Mr. William J. Regan, Chief Compliance Officer (Age 69)

Who are some of Navidea Biopharmaceuticals' key competitors?

What other stocks do shareholders of Navidea Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Navidea Biopharmaceuticals investors own include OPKO Health (OPK), Ampio Pharmaceuticals (AMPE), CorMedix (CRMD), Catalyst Pharmaceuticals (CPRX), FuelCell Energy (FCEL), Palatin Technologies (PTN), Trevena (TRVN), Agenus (AGEN), Dynavax Technologies (DVAX) and Genocea Biosciences (GNCA).

What is Navidea Biopharmaceuticals' stock symbol?

Navidea Biopharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NAVB."

How do I buy shares of Navidea Biopharmaceuticals?

Shares of NAVB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Navidea Biopharmaceuticals' stock price today?

One share of NAVB stock can currently be purchased for approximately $1.71.

How much money does Navidea Biopharmaceuticals make?

Navidea Biopharmaceuticals has a market capitalization of $49.63 million and generates $920,000.00 in revenue each year. The biopharmaceutical company earns $-10,720,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis.

How many employees does Navidea Biopharmaceuticals have?

Navidea Biopharmaceuticals employs 13 workers across the globe.

What is Navidea Biopharmaceuticals' official website?

The official website for Navidea Biopharmaceuticals is www.navidea.com.

Where are Navidea Biopharmaceuticals' headquarters?

Navidea Biopharmaceuticals is headquartered at 4995 Bradenton Ave Ste 240, DUBLIN, OH 43017-3552, United States.

How can I contact Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals' mailing address is 4995 Bradenton Ave Ste 240, DUBLIN, OH 43017-3552, United States. The biopharmaceutical company can be reached via phone at +1-614-7937500 or via email at [email protected]

This page was last updated on 7/28/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.